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1. Introduction  
The prevalence of diabetes mellitus has reached epidemic proportions and constitutes a 
major public health problem. Diabetes mellitus affects an estimated 171 million people 
worldwide in 2000 and this number is projected to double to 366 million by 2030 (Wild et al., 
2004). Silent myocardial ischemia is common in diabetic patients and may delay or mask the 
diagnosis of coronary artery disease, particularly in its early stages.  
2. Diabetes, a coronary artery disease risk equivalent  
Coronary artery disease is the leading cause of morbidity and mortality in individuals with 
type 2 diabetes mellitus. Coronary artery disease is more severe, more prevalent and occurs 
at younger age in patients with type 2 diabetes mellitus. Using a range of diagnostic 
methods, the overall prevalence of coronary artery disease is reported to be as high as 55% 
in patients with diabetes, compared with 2% to 4% in the general population (Hammoud et 
al., 2000). In an asymptomatic and uncomplicated cohort of type 2 diabetic patients, 46, 3% 
had evidence of coronary calcification indicative of coronary atherosclerosis (Anand et al., 
2006). In an autopsy study of diabetic patients the prevalence of anatomic coronary artery 
disease was 50% to 81% (Goraya et al., 2002).  
An estimated 80% of diabetic patients die from cardiovascular disease, 75% of which is 
attributed to coronary artery disease (American Diabetes Association, 1998). In general 
diabetic patients have more extensive atherosclerosis with a higher prevalence of 
multivessel coronary artery disease, frequent silent myocardial ischemia and infarction 
with a higher cardiac event rate when compared with non-diabetic patients (Goraya et. al, 
2002; Nesto et al., 1998; Stamler et al., 1993). Patients with diabetes without previous 
myocardial infarction or cardiovascular disease have been shown to have a similar 
prognosis as persons without diabetes but with prior myocardial infarction or 
cardiovascular disease (Haffner et al., 1998). Based on these data, diabetes is considered a 
coronary artery disease risk-equivalent according to current Framingham Risk Score 
Adult Treatment Program III guidelines and secondary prevention of coronary artery 
disease is recommended for all adult diabetic patients 
(http://www.nhlbi.nih.gov/giudelines/cholesterol/atp3_rpt.htm). 
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3. Silent ischemia - prevalence and prognosis in diabetic patients  
Silent ischemia is a common, under-recognized condition that is associated with an adverse 
prognosis. It is a marker of a significant underlying coronary artery disease and therefore of 
future cardiovascular events. Myocardial ischemia is often asymptomatic in patients with 
diabetes mellitus and coronary artery disease is frequently in an advanced stage when it 
becomes clinically manifest.  
A number of studies have confirmed the presence of silent ischemia in diabetic patients. The 
reported prevalence of myocardial ischemia varied between studies from 6% to 59% 
(MiSAD group, 1997; Miller et al, 2004; Rajagopalan et al., 2005; Zellweger et al., 2004; 
Wackers et al., 2004; Scognamiglio et al., 2006). This variation is probably related to 
differences in patient selection, stress methodology and imaging techniques. Autopsy 
studies have identified a high prevalence of coronary atherosclerosis in patients with 
diabetes, even among those without clinical coronary heart disease. Almost 75% of diabetic 
decedents without clinical coronary artery disease have high grade coronary atherosclerosis 
(Goraya et al., 2002).  
The importance of identifying silent ischemia is highlighted by the poor outcomes 
associated with silent ischemia in patients with type 2 diabetes. Silent ischemia was 
significantly related to future coronary events in asymptomatic diabetic patients after 2, 8 
years (risk ratio: 21) (Rutter et al., 1999). Similarly, 5-year follow-up of the MISAD (Milan 
Study on Atherosclerosis and Diabetes) cohort showed that abnormal baseline 
scintigraphy was associated with fivefold increase in fatal and nonfatal cardiac events 
(risk ratio: 5,47) (Faglia et al., 2002). Diabetic patients with inducible ischemia on stress 
myocardial perfusion imaging using single-photon emission computed tomography 
(SPECT) have a significantly higher annual cardiac death or myocardial infarction rate 
than nondiabetic patients with ischemia (10% vs. 8%)(Shaw & Iskandrian, 2004). In one 
study of female diabetic patients with high-risk stress SPECT perfusion scan characterized 
by a multivessel disease pattern only 60% survived without infarction in the next 3 years. 
For male diabetic patients with high-risk scan this value was 79% (Giri et al., 2002).  
Similarly diabetic patients with abnormal stress echocardiography have a worse 
prognosis that non-diabetic patients (Cortigiani et al., 2006). Diabetic patients with 
coronary atherosclerosis as determined by computed tomography calcium scanning have 
a worse outcome regarding cardiac death and nonfatal infarction that non-diabetic 
patients with the same coronary artery calcium score (Raggi et al., 2004). Compared with 
nondiabetic patients diabetic patients with zero coronary artery calcium score had a 
similar annual mortality rate of 0, 36%. It seems that 48% of diabetic patients had coronary 
artery calcium score compatible with significant coronary artery disease (Khaleeli et al., 
2001).  
The exact reason for the poor prognosis associate with silent ischemia is unclear. Silent 
ischemia confirms the presence of significant coronary artery disease and therefore this 
population is more at risk for future coronary events. Also repeat episodes of silent ischemia 
could lead to progressive fibrosis which can progress to left ventricular systolic dysfunction 
or life threatening arrhythmias. Myocardial biopsies from hypokinetic territories supplied 
by stenosed coronary arteries have shown areas of fibrosis and myocite death in the absence 
of infarction (Schaper, 1988). 
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4. Diagnostic of silent ischemia, which test should be used in which diabetic 
patient  
There are numerous non-invasive test available for myocardial ischemia detection: exercise 
stress test, Holter ECG monitoring, stress myocardial perfusion imaging, stress 
echocardiography and other non-invasive techniques can detect the atherosclerotic disease: 
as carotid-intimae-media thickness evaluation via high resolution ultrasound or coronary 
artery calcium scoring via computed tomography or computed tomography coronary 
angiography. It is unclear if for screening the detection of early markers of coronary artery 
disease is preferred over the actual visualisation of myocardial ischemia.  
4.1 Exercise stress test  
Exercise stress test is the most widely available, inexpensive and commonly used test used 
to detect coronary artery disease. It has been well validated in the general population and it 
can be used as the first diagnostic test for patients with an intermediate risk of having 
coronary artery disease. Given the differences in presentation of coronary artery disease 
within the diabetic population and the high incidence of silent myocardial ischemia, various 
groups have attempted to evaluate whether exercise ECG has similar accuracy in a diabetic 
population. Few data exist regarding the relationship between exercise ECG test results and 
coronary artery disease risk in persons with type 2 diabetes mellitus and most studies have 
involved small samples.  
In a prospective study (Blandine et al., 1999) 203 diabetic patients without angina and with 
normal resting ECG were screened with exercise ECG test (stress nuclear imaging was used 
if exercise ECG was contraindicate or inconclusive). Sixteen percent had abnormal stress test 
whereas 9% had silent coronary artery disease as defined by angiography. In a study (Bacci 
et al., 2002) which evaluated 206 higher risk asymptomatic type 2 diabetes patients with 
peripheral arterial disease and at least 2 cardiovascular risk factors, 19% had an abnormal 
test and the positive predictive accuracy of the exercise ECG was 79%. These studies 
collectively support the notion that among higher-risk cohorts of asymptomatic patients 
with type 2 diabetes nearly 1/3 may have unrecognized coronary artery disease and 
exercise ECG may be useful in identifying these patients. In an evaluation of the correlation 
between the ECG exercise stress test and coronary angiography in 59 diabetic patients the 
sensitivity and specificity were 75% and 77% (Paillole et al., 1995). The mean positive 
predictive value of exercise ECG for predicting angiographic coronary disease varies 
between 70 and 90% (Bacci et al., 2002; Blandine et al., 1999).  
Regarding the prognostic value of exercise stress test a study on 68 asymptomatic male 
veterans (Rubler et al., 1987) with diabetes mellitus found that exercise ECG testing had 50% 
sensitivity and 83% specificity for predicting subsequent cardiac events over an average of 
41 months of follow-up.  In the Milan study on Atherosclerosis and Diabetes (Faglia et al., 
2002) 735 asymptomatic diabetic patients were screened for coronary artery disease and 
followed-up for 5 years. In all patients exercise ECG was performed with a positive test 
prompting stress nuclear testing. Among the subjects with normal exercise ECG test the 
incidence of cardiac events was significantly lower compared to those with abnormal stress 
testing (p<0, 0001). These data suggest that asymptomatic patients with uncomplicated type 
2 diabetes who have a negative exercise ECG test have a lower cardiac event rate and 
relatively favourable prognosis.  
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In diabetic patients the value of exercise ECG testing is limited because its low sensitivity 
requires a workload that is difficult to achieve owing to comorbidities such as peripheral 
neuropathy, peripheral arterial diseases, poor physical fitness and obesity. The specificity of 
exercise testing is limited and false positive results are common in patients without angina. 
Furthermore the specificity is lower in diabetes because of the presence of microvascular 
disease (Bacci et al., 2002). Exercise ECG has moderate sensitivity and specificity for 
detection of coronary artery disease. During intermediate follow up exercise ECG has been 
shown to have a good predictive value for coronary events.  It can identify a subgroup of 
asymptomatic diabetic patients who have significant coronary artery disease as defined by 
angiography and in lower risk diabetic cohorts it may offer short term prognostic 
reassurance to those asymptomatic patients with negative test. Parameters including 
exercise capacity and heart rate recovery offer significant information particularly in 
diabetic patients who may not experience angina during exercise and who may have 
increased autonomic dysfunction (Albers et al., 2006). Application of exercise ECG as a 
screening tool in type 2 diabetes is limited as the test is often inconclusive (Djaberi et al., 
2008). 
4.2 Holter ECG monitoring  
The prevalence of silent myocardial ischemia as assessed by Holter ECG monitoring varies 
between 35% and 58% (Chiariello et al., 1985; Aronow et al., 1992). Comparison between 
diabetic patients and nondiabetic individuals in Asymptomatic Cardiac Ischemia Pilot 
(ACIP) study showed that despite more extensive and diffuse coronary disease, diabetic 
ACIP patients tended to have less measurable ischemia during the 48-hour ambulatory ECG 
(Caracciolo et al, 1996). Comparing exercise ECG and ambulatory ECG for detection of silent 
ischemia in diabetes a study revealed that ambulatory ECG identified ischemia only in 
diabetics with three vessel disease but exercise ECG also revealed ischemia in one or two 
vessel disease (Ahluwalia et al., 1995). Regarding the prognostic value, in one study patients 
with silent ischemia detected on ambulatory ECG had a higher incidence of new coronary 
events (87%) than those without silent ischemia (51%) during 40 month follow-up period 
(Aronow et al., 1992). Further studies are necessary to evaluate the prognostic value of silent 
ischemia detected by ambulatory ECG.  
In conclusion the diagnostic value of ambulatory ECG for coronary heart disease is poor. 
The predictive value of ischemia detected by ambulatory ECG has not been extensively 
evaluated (Djaberi et al., 2008). 
4.3 Stress echocardiography  
Stress echocardiography imaging provides improved sensitivity and specificity compared 
with exercise ECG testing. There are limited data regarding the utility of stress 
echocardiography in patients with diabetes particularly in those who are asymptomatic. In a 
study, 52 patients with diabetes were referred for cardiac assessment using dobutamine 
stress echocardiography (Hennessy et al., 1997). Sensitivity, specificity and positive and 
negative predictive values of dobutamine stress echocardiography for coronary artery 
disease detection were 82%, 54%, 84% and 50% respectively. Although the study was 
limited by the small size of the cohort it demonstrated similar diagnostic accuracy for 
dobutamine stress echocardiography in a diabetic population as in the general population. 
In another study on 55 diabetics who underwent dobutamine stress echocardiography and 
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angiography the sensitivity and specificity of stress echocardiography were 81% and 85% 
(Elhendy et al., 1998). The efficacy of dobutamine stress echocardiography was compared to 
exercise ECG testing and SPECT nuclear perfusion imaging in 56 asymptomatic diabetic 
patients with three additional cardiovascular risk factors but normal resting ECG. 
Participants underwent all forms of noninvasive stress testing but coronary angiography 
was only performed if at least one test was abnormal (47%), which precluded the 
measurement of diagnostic sensitivity and specificity. Positive predictive value was 69% for 
dobutamine stress echocardiography, 60% for exercise ECG and 75% for thallium SPECT 
(Penfornis et al., 2001).  
A study was performed on 1899 asymptomatic diabetic patients which underwent 
dipyridamole myocardial contrast echocardiography and in those with myocardial 
perfusion defects the anatomy of coronary vessels was analyzed by coronary angiography 
(Scognamiglio et al., 2006).  Patients were divided in two groups according to the number of 
risk factors for coronary artery disease. In the two study groups the prevalence of abnormal 
myocardial contrast echocardiography (59 vs. 60%) and of significant coronary artery 
disease (64, 6% vs. 65, 5%) was similar irrespective of risk profile. The criteria of ≥ 2 risk 
factors did not help to identify asymptomatic patients with a higher prevalence of coronary 
artery disease and is only related to a more severe coronary artery disease with 
unfavourable coronary anatomy. The findings of this study suggest that a substantial 
number of asymptomatic diabetic patients have myocardial perfusion defects and 
significant coronary artery disease independent of risk factor profile. As a consequence a 
large number of asymptomatic diabetic patients with few risk factors might have occult 
coronary artery disease and might be missed on the basis of 1998 American diabetes 
association guidelines (ADA, 1998).  
Several studies have evaluated the prognostic value of stress echocardiography among 
diabetic patients. In a prospective study stress echocardiography plus an exercise ECG were 
used to screen 71 diabetic patients with unknown asymptomatic cardiac disease and two or 
more cardiovascular risk factors. Those who obtained an abnormal result in one test 
underwent coronary angiography and if necessary revascularization. Compared with 
patients randomised to the control arm (n=70) coronary events were significantly reduced in 
the screening arm during follow-up (Faglia et al, 2005). The preclinical diagnosis of coronary 
artery disease by stress echocardiography may therefore be effective. However more studies 
are needed to determine the prognostic role of stress echocardiography in screening for 
cardiac disease in asymptomatic diabetic patients.  
Stress echocardiographic imaging provides improved sensitivity and specificity compared 
with exercise ECG testing.  Increasing data are available to support both its diagnostic 
accuracy and its prognostic role. The presence of resting left ventricular systolic dysfunction 
and stress induced wall motion abnormalities provides incremental prognostic information 
to clinical and exercise parameters in multiple studies. Patients referred for pharmacological 
stress echocardiography demonstrate a higher risk for cardiovascular events than those 
referred for exercise testing which likely reflects more severe underlying cardiovascular 
disease and comorbidities. Diabetic patients with normal stress echocardiography appear to 
have a greater risk for subsequent cardiovascular events than non-diabetic patients, 
particularly beyond 2 years. The sensitivity and specificity of stress echocardiography for 
diagnosing extensive coronary artery disease are satisfactory. However the predictive value 
of a positive test in type 2 diabetes needs to be further analysed (Djaberi et al., 2008). 
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4.4 Nuclear single photon emission computed tomography (SPECT) myocardial 
perfusion imaging   
Nuclear SPECT myocardial perfusion imaging has been employed in several series to test 
the prevalence of silent ischemia or to analyse the prognostic impact of perfusion 
abnormalities in diabetes. It is known that perfusion abnormalities precede abnormalities in 
systolic function in the ischaemic cascade (Nesto & Kowalchuk, 1987). Accordingly 
comparisons between myocardial perfusion imaging and stress echocardiography have 
shown a higher sensitivity for myocardial perfusion imaging for the detection of multi-
vessel and single-vessel coronary artery disease (Schinkel et al., 2003). 
In asymptomatic diabetic patients the rate of silent myocardial ischemia diagnosed by stress 
myocardial perfusion imaging ranges from 6 to 59% (Zellweger et al., 2004; Faglia et al., 
2002; , De Lorenzo et al., 2002; Wackers et al., 2004; Rajagapolan et al., 2005; Vanzetto et al., 
1999; Cosson et al., 2004). This wide range in the prevalence of silent ischemia is related to 
differences in patient selection, stress methodology and imaging techniques. In retrospective 
data base analyses of patients with diabetes referred for stress testing a high prevalence (41-
58%) of abnormal stress myocardial perfusion imaging and a high cardiac event rate were 
found (Giri et al., 2002; Kang et al., 1999; Rajagapolan et al., 2005). A retrospective analysis 
performed by on 1427 diabetic patients referred for myocardial perfusion imaging reported 
an abnormal in 58% and high risk scan in 18% of subjects (Rajagopalan et al., 2005). Sixty-
one percent of patients with high risk results had angiographically high risk coronary artery 
disease. According to SPECT imaging scans patients were categorized as being at high, 
intermediate or low risk with significant difference regarding annual mortality rate(p<0,001) 
between groups. It is likely that these patients were referred for stress testing because of 
typical or atypical symptoms and/or perceived clinical high risk.   
The retrospective database analyses of known asymptomatic patients with diabetes referred 
for stress testing showed a lower prevalence of abnormal stress myocardial perfusion 
imaging and cardiac event rate (Zellweger et al., 2004; Miller et al., 2004; De Lorenzo et al., 
2002, Prior et al., 2005). These patients may not be representative of asymptomatic patients 
with diabetes in the larger population because they were referred for stress myocardial 
perfusion imaging for example before noncardiac surgery. The mean prevalence of ischemia 
ranged from 26-39% although Miller et al. reported abnormal myocardial perfusion imaging 
in 59% asymptomatic patients. But in the study performed by Miller et al. higher risk 
population was studied including patients with antianginal medication and ECG 
abnormalities (Q waves, ST-T changes). Because of the retrospective nature of these two 
types of studies the true prevalence of silent ischemia is uncertain. In general a higher 
percentage of perfusion defects have been detected in retrospective studies.   
Several prospective studies showed lower prevalence of silent coronary artery disease 
ranging from 6 to 22%. There were important differences in design and stress testing 
methodology. In the Milan study on Atherosclerosis and Diabetes (MiSAD) asymptomatic 
patients with diabetes were first screened with exercise stress test and only if this test was 
abnormal stress myocardial perfusion imaging was performed. It is possible that because 
the low sensitivity of exercise ECG the overall observed prevalence of silent coronary artery 
disease was low 6% (Faglia et al., 2002). In DIAD (Detection of Ischemia in Asymptomatic 
Diabetics) a large prospective study, 1124 type 2 diabetic asymptomatic patients were 
enrolled. Half of the patients were randomized to an adenosine Tc 99 m sestamibi 
myocardial perfusion imaging and half were not. In the imaging cohort 22% of the 
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individuals showed abnormal myocardial perfusion imaging and 1 in every 18 subjects (5, 
5%) showed moderate to severe perfusion defects indicative of a poor prognosis. Coronary 
artery disease would remain undetected in as many as 41% of type 2 diabetic patients if 1998 
American Diabetes Association recommendations for coronary artery disease screening 
were strictly followed. Although the study could not demonstrate benefit from routine 
screening stress myocardial perfusion imaging allowed a good stratification of risk. The 12% 
participants with moderate or large perfusion defects had higher event rates (2, 4% per year) 
compared with participants with small or no defects that had low event rates (0, 4% per 
year) (Wackers et al., 2004). In a study, 510 asymptomatic patients with diabetes had pre-
screening performed using electron-beam computed tomography. If the coronary artery 
calcification score was 100 Agatston units or greater stress myocardial perfusion imaging 
was performed (Anand et al., 2006). The prevalence of silent coronary artery disease in this 
study was 13% and established cardiovascular risk factors failed to predict silent ischemia. 
These two recent prospective studies indicated that the prevalence of silent coronary artery 
disease in asymptomatic patients is considerably lower than was suggested by retrospective 
database analyses. Regarding the prognostic role of myocardial perfusion imaging, in 
pooled studies including both diabetic and non-diabetic patients and symptomatic as well 
as asymptomatic patients a normal stress myocardial perfusion imaging has been associated 
with a cardiac event rate of < 1% per year (Iskander & Iskandrian, 1998). With abnormal 
stress myocardial perfusion imaging studies the extent and severity of myocardial ischemia 
strongly predicts short and long term risks of coronary events (Hachamovitch et al., 1998). A 
study was performed on 180 asymptomatic adult-onset diabetic patients referred to exercise 
myocardial perfusion imaging to detect asymptomatic obstructive coronary artery disease 
(De Lorenzo et al., 2002). In this study a short-term follow-up was conducted to correlate the 
imaging findings with patients outcome. A positive test result was reported in 26% of all 
subjects and clinical variables were not associated with the type of defect or subsequent 
events. During follow-up two percent of hard events and 5% of total events occurred in 
patients with normal SPECT. These numbers increased to 9% of hard events and 38% of 
total events in those with an abnormal SPECT. Male sex and perfusion abnormalities were 
independent predictors of cardiac events. The presence of an abnormal SPECT in 
asymptomatic patients seemed to provide added prognostic value over clinical predictors 
alone. In a multicenter cohort consisting of 370 asymptomatic patients with diabetes with at 
least two additional cardiovascular risk factors silent ischemia was identified in 35% of 
patients using stress SPECT imaging as well as ECG stress testing (Valensi et al., 2005). 
During follow-up there was a significant association between positive stress test results and 
subsequent cardiac events only in patients > 60 years.  
Myocardial perfusion imaging showed good sensitivity but poor specificity (possibly 
because microvascular disease) for diagnosing coronary artery disease in diabetes. 
Intermediate follow-up has shown good predictive value of myocardial perfusion imaging 
for coronary events in type 2 diabetes (Djaberi et al., 2008). 
4.5 Coronary artery calcium scores  
The presence of coronary calcium is indicative of coronary atherosclerosis. Coronary 
calcification can be detected noninvasively be electron beam computed tomography and 
more recently multislice computed tomography. Diabetic patients without manifest 
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coronary artery disease have a higher coronary artery calcium score that non-diabetic 
independent of classical risk factors (Hoff et al., 2003; Schurgin et al., 2001, Reaven & Sacks, 
2005). Also coronary artery calcium scores show significantly more progression over time in 
patients with diabetes that in nondiabetics (Raggi et al., 2005).  
A substantial body of evidence has established that coronary artery calcium measurement 
provides potent risk stratification for asymptomatic diabetics. In a cohort of 10.377 
asymptomatic individuals which included 903 diabetics the mean coronary artery calcium 
score was significantly higher in subjects with diabetes than in those without diabetes and 
for every increase in coronary artery calcium score there was a greater increase in mortality 
for diabetic patients than for nondiabetic patients (Raggi et al., 2004).  
In the presence of multiple cardiac risk factors, the prevalence of coronary artery calcium 
is increased. In asymptomatic patients with three or more cardiac risk factors the 
prevalence of coronary artery calcium was significantly increased (Moser et al., 2003). An 
Agatston score greater than 400 is a threshold for further testing with myocardial 
perfusion imaging (Moser et al., 2003). These data suggest that coronary artery calcium 
scoring may have value as an approach to enrich target population of asymptomatic 
patients with diabetes for screening.  
Currently only limited data are available on the relative values of coronary artery calcium 
and myocardial perfusion imaging for detection silent coronary artery disease and 
prognostic evaluation. Wong et al. studied 1043 patients without known coronary artery 
disease (140 patients with diabetes) with coronary artery calcium scoring and stress 
myocardial perfusion imaging (Wong et al., 2005). A coronary artery calcium score lower 
than 100 was associated with absence of stress induced ischemia on myocardial perfusion 
imaging. The likelihood of stress-inducible ischemia increased in parallel with increasing 
coronary artery calcium score and was greater in diabetics. A recent study explored the 
combined use of coronary artery calcium assessment and myocardial perfusion imaging in 
asymptomatic patients with diabetes (Anand et al., 2006). The study evaluated 510 
asymptomatic patients with type 2 diabetes using initially electron beam computed 
tomography to assess coronary artery calcium. If coronary artery calcium score was greater 
than 100 (25%) stress myocardial perfusion imaging was performed. For comparison, 53 
randomly selected patients with a coronary artery calcium score of 100 or less also 
underwent stress myocardial perfusion imaging. Patients with coronary artery calcium 
score of 10 or less had no abnormalities on myocardial perfusion imaging. The prevalence of 
abnormal myocardial perfusion imaging studies increased at higher coronary artery calcium 
scores. From patients with a coronary artery calcium score between 101 and 400, 23% had 
abnormal myocardial perfusion imaging and this number increased to 71, 4% of patients 
with a coronary artery calcium score greater than 1000. Sequential use of electron beam 
computed tomography and myocardial perfusion imaging may optimize screening of 
asymptomatic diabetic patients. During a mean follow-up of 18±5 months, no events 
occurred in patients with coronary artery calcium score of 10 or less; as compared with 82% 
of events occurring in patients with a coronary artery calcium score greater than 400. The 
coronary artery calcium score and the extent of myocardial perfusion imaging abnormalities 
were the only predictors of future cardiac events (Anand et al., 2006). The calcium score was 
demonstrated to be superior to the established risk factors in predicting silent ischemia and 
cardiac events. Other studies (He et al., 2000; Berman et al., 2004) found also that the 
prevalence of stress-induced ischemia on myocardial perfusion was very low if the coronary 
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artery calcium score was lower than 100 Agatston units and increased in parallel to the 
coronary artery calcium score. Of patients with coronary artery calcium score 400 or greater, 
46% had demonstrable stress-induced myocardial ischemia on myocardial perfusion 
imaging (He et al., 2000). The decision to perform coronary artery calcium scoring should be 
based on clinical judgment, only if the results have the potential to change the management 
of the patient (Bax et al., 2007). 
4.6 Multislice computed tomography coronary angiography  
In type 2 diabetes multislice computed tomography angiography has demonstrated a higher 
percentage of noncalcified and calcified plaques and a relatively lower percentage of mixed 
plaques in diabetes (Pundziute et al., 2007) which can be explained by the rapid progression 
of atherosclerosis. The sensitivity and specificity is 81% and 82% respectively for detection 
of coronary stenosis (Schuijf et al., 2004). The diagnostic accuracy of multislice computed 
tomography angiography is similar in diabetic and nondiabetic individuals (Schuijf et al., 
2005). Importantly negative predictive value of multislice computed tomography 
angiography in diabetes was to be found 98% - 100 %( Berman et al., 2004). The prevalence 
of coronary heart disease has been assessed by multislice computed tomography 
angiography in 70 asymptomatic patients with type 2 diabetes. The majority of the patients 
(80%) had atherosclerosis: obstructive coronary artery disease in 26% and nonobstructive 
coronary heart disease in 54% of patients (Wong et al., 2005).  
Thus, results on the use of noninvasive multislice computed tomography angiography for 
coronary heart disease screening and as a prognostic indicator in the diabetic population 
appear promising but further studies in larger population groups are needed.  
Multislice computed tomography angiography has good sensitivity, specificity and negative 
predictive value for identification of coronary heart disease in diabetic patients. However 
assessment of coronary heart disease by multislice computed tomography in asymptomatic 
type 2 diabetic patients should be limited to patients at high-risk because of exposure to 
high radiation and contrast as well as cost factors (Djaberi et al., 2008). 
4.7 Carotid intimae-media thickness in type 2 diabetes 
Mean common carotid intimae-media thickness in middle aged individuals is higher in 
diabetic patients versus controls. In diabetics without a history of myocardial infarction 
carotid intimae-media thickness is similar to that in non-diabetic with a history of 
myocardial infarction (Lee et al., 2004). Progression of maximal carotid intimae-media 
thickness in the Insulin Resistance Atherosclerosis Study was twice as high in person with 
diabetes versus controls (Wagenknecht et al., 2003) but other studies report lower rates (van 
der Meer et al., 2003). In type 2 diabetes prevalent cardiovascular disease is associated with 
a higher carotid intimae-media thickness (Lee et al., 2004). Carotid intimae-media thickness 
was shown to be an independent predictor of cardiovascular events (Bernard et al., 2005). 
Folsom and colleagues analysed carotid intimae-media thickness in a large cohort that 
included 1500 diabetic participants and they found that carotid intimae-media thickness has 
predictive value for future coronary events only in combination with other novel risk factors 
(Folsom et al., 2003). Carotid intimae media thickness is increased in type 2 diabetic patients 
with cardiovascular disease and is an independent predictor of coronary events. However 
the magnitude of its predictive value when added to other risk factors is questionable 
(Djaberi et al., 2008). 
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4.8 Arterial stiffness in type 2 diabetes 
Diabetic patients have increased arterial stiffness (Weber et al., 2004, Cruickshank et al., 
2002). Compromised carotid distensibility and pulse wave velocity have been demonstrated 
even before the onset of diabetes, in patients with impaired glucose tolerance. Arterial 
stiffness in diabetes is related to prevalent cardiovascular disease (Fukui et al., 2003) and has 
shown to be an independent predictor of coronary heart disease (Hatsuda et al., 2006). Pulse 
wave velocity does seem to have a reasonable value for mortality prediction in patients with 
impaired glucose tolerance and type 2 diabetes (Cruickshank et al., 2002). Vascular stiffness 
is increased in type 2 diabetic patients with cardiovascular disease and has been shown to 
predict cardiovascular mortality (Djaberi et al., 2008)  
4.9 Flow mediated dilation in type 2 diabetes 
Type 2 diabetes is associated with endothelial dysfunction. Insulin-mediated dilation being 
at least in part nitric-oxid dependent, insulin resistance may cause endothelial dysfunction. 
Clustering of risk factors such as dyslipidemia, hypertension and obesity in the metabolic 
syndrome play an additional role. The predictive value of endothelial dysfunction in 
epicardial coronary arteries of diabetic patients has been established for long-term coronary 
events (Nitenberg et al., 2005). Flow mediated dilation is a marker of endothelial 
dysfunction. The potential of flow mediated dilation for the identification of type 2 diabetic 
patients at risk for cardiovascular disease is unknown. 
Surrogate markers of atherosclerosis: carotid intimae media thickness, arterial stiffness and 
flow mediated dilation are abnormal long time before the onset of diabetes. These 
measurements can be useful for the identification of at risk patients during early stages of 
atherosclerosis. Further studies are necessary to evaluate whether these measurements will 
provide any additional prognostic value in combination with risk scores (Djaberi et al., 2008).  
4.10 Coronary angiography  
Coronarography is an invasive diagnostic tool, the gold standard for identifying obstructive 
lesions and will be considered in the presence of ischemia revealed by noninvasive 
screening tests.  
4.11 Cardiovascular magnetic resonance imaging  
Cardiovascular magnetic resonance imaging studies can provide information regarding 
coronary stenoses and flow, evaluation of myocardial perfusion and metabolism, wall 
motion during stress and evidence of infarction. There are limited data to support the use of 
cardiovascular magnetic resonance in asymptomatic patients.  
4.12 Biomarkers  
A simple, inexpensive blood test for B type natriuretic peptide (BNP) or N terminal 
prohormone B type natriuretic peptide (NT-proBNP) is a candidate for screening tool of 
silent myocardial ischemia. BNP is of value in predicting silent ischemia at exercise testing 
in type 2 diabetic patients (Rana et al., 2006). Hamano et al. showed in a recent study that 
NT-proBNP has a very high negative predictive value which enables to focus on patients 
with silent ischemia independent of microalbuminuria (Hamano et al., 2010).  Cosson et al. 
conclude that NT-proBNP helps to better define diabetic patients with silent ischemia 
independently of cardiac structure and function (Cosson et al., 2009).  
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5. Deciding who to investigate? Which are the patients with diabetes at high 
risk that should be screened? 
Population screening is not feasible but diabetic patients with high risk of silent ischemia 
should be identified and investigated further. It still remains under debate what would be 
the best strategy for proper patient selection to screening and if screening will alter patient 
outcome when added to primary preventive measures. Several studies of asymptomatic 
patients with type 2 diabetes have specifically examined whether risk factor burden is 
predictive of silent ischemia (determined by myocardial perfusion imaging) and these 
studies have not supported the recommendation of the 1998 ADA consensus panel for 
screening asymptomatic patients with two or more risk factors (Rajagopalan et al., 2005; 
Scognamiglio et al., 2006). In asymptomatic patients with diabetes mellitus clinical features 
that help to identify the patient with increased risk for myocardial infarction or cardiac 
death include: evidence of other atherosclerotic disease, microalbuminuria and chronic renal 
disease, abnormal resting ECG, diabetes complications including autonomic neuropathy, 
rethinopathy, age, sex, unexplained dyspnoea and multiple both traditional and novel risk 
factors (Bax et al., 2007).  
Atherosclerotic disease involving lower extremity, cerebral, renal or mesenteric arteries 
identifies a patient with diabetes who is at increased risk for adverse cardiovascular 
outcomes and might have advanced coronary atherosclerosis (Golomb et al., 2006). Other 
atherosclerotic location is of bad prognosis in asymptomatic diabetic patients leading to 
increased silent myocardial ischemia and cardiovascular event rates (Criqui et al., 1992). A 
diminished ankle-brachial index is sensitive indicator of increased risk for future 
cardiovascular events (Doobay & Anand, 2005). In patients with claudication or 
asymptomatic peripheral arterial disease, 90% of deaths are attributable to coronary artery 
disease (Mann et al., 2001).  
Microalbuminuria predicts increased risk for vascular disease complications (Schuijf et al., 
2006, Anand et al., 2006, Gerstein et al., 2001) as well as for the progression to overt 
nephropathy in patients with diabetes. Microalbuminuria has been a predictor of inducible 
ischemia in some (Rutter et al., 1999) but not all (Wackers et al., 2004) studies of 
asymptomatic patients with diabetes. An increased microalbuminuria predicts a high 
cardiovascular event rate with a two-time earlier mortality rate (Dinneen & Gerstein, 1997).  
Asymptomatic patients with type 2 diabetes occasionally have evidence of previously 
unrecognized myocardial infarction on resting ECG, including abnormal Q waves or deep 
T-wave inversions or left bundle branch block. These findings should trigger evaluation for 
coronary artery disease and inducible ischemia. In a retrospective study of 1427 
asymptomatic patients who were referred to the Mayo Clinic for stress testing, Rajagopalan 
and colleagues aimed to define the variables that would characterize which asymptomatic 
diabetic patients are most suitable for screening with stress myocardial perfusion imaging.  
They conducted multivariate analysis and found that high-risk scans were most strongly 
associated with seven independent variables, the most notable being electrocardiographic Q 
waves and peripheral arterial disease. Although this was a retrospective study and many 
have been influenced by verification bias, it provides additional support for identifying 
high-risk asymptomatic diabetic patients with electrocardiographic abnormalities, 
peripheral arterial disease, among other clinical variable. Nonspecific ST-T wave changes 
also are a strong predictor of inducible ischemia in asymptomatic diabetic patients 
(Rajagopalan et al., 2005).  
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Cardiovascular autonomic neuropathy is associated with poor overall prognosis in patients 
with type 2 diabetes (Vinik et al., 2003). That is probably due to impairment in ischemia 
awareness delaying the diagnosis of coronary artery disease or hemodynamic lability due to 
blunted parasympathetic activation. Autonomic neuropathy might also be a parallel 
consequence of cardiac risk factors including hyperglycaemia, dyslipidemia and renal 
disease. Several studies have implicated autonomic neuropathy as a contributing factor in 
the mechanism of silent ischemia (Marchant et al, 1993; O'Sullivan et al., 1991). Autonomic 
neuropathy was a major predictor of inducible ischemia in DIAD (Detection of Ischemia in 
Asymptomatic Diabetics) (Wackers et al., 2004) and has been associated with abnormal 
cardiac test findings in other (Valensi et al., 2001) but not all (MiSAD Group, 1997) studies. 
Cardiac autonomic neuropathy should be considered in the presence of unexplained 
tachycardia, orthostatic hypotension and other autonomic or peripheral neuropathies.  
Diabetic retinopathy is a manifestation of microvascular disease but is also an indicator of 
risk for coronary artery disease. In clinical studies retinopathy has been associated with 
inducible ischemia in some (Akasaka et al., 1997) but not all screening studies. In a recent 
study that assessed the prevalence and risk factors predictors of true silent myocardial 
ischemia in asymptomatic type 2 diabetic patients, the prevalence of silent ischemia was 21, 
9% and male gender and the presence of diabetic retinopathy were the risk factors related to 
its development (Hernandez et. al, 2011). Hyperglycaemia is a stronger predictor of 
microvascular disease than atherosclerotic macrovascular disease in people with diabetes 
(Laakso, 1999). 
Although diabetes increases relative cardiovascular risk more in women than in men the 
absolute risk for cardiovascular events is still higher in men than in women (Abbott et al., 
1988). Male sex and duration of diabetes were also strong predictors of silent ischemia in 
DIAD, but traditional risk factors, novel biomarkers (hs C reactive protein, homocysteine, 
lipid subtractions, and plasminogen activator inhibitor-10) and  the number of risk factors 
were not predictive of abnormal myocardial perfusion (Wackers et al., 2004). Age is an 
important determinant of cardiovascular risk and the prevalence of inducible ischemia is 
significantly higher in patients with type 2 diabetes >65 years (Chaowalit et al., 2006). 
Patients with exertional symptoms as shortness of breath, generalized fatigue should be 
screened for ischemia. It is difficult to attribute these symptoms to myocardial ischemia (an 
angina equivalent) or to obesity and deconditioning. But however patients who are unable 
to exercise are at increased cardiac risk. The incidence of inducible ischemia is increased in 
these patients and when present is associated with poor prognosis (Vanzetto et al., 1999).  
Patients with type 2 diabetes often have multiple cardiac risk factors including 
hypertension, dyslipidemia, inactivity, smoking and abdominal obesity. Multiple risk 
factors in the same patient substantially increase the overall cardiovascular risk (Multiple 
Risk Factor Intervention Trial, 1996).  Also intervention directed at multiple risk factors 
significantly improves cardiovascular prognosis (Gaede et al., 2003). A prospective smaller 
study performed on 120 truly asymptomatic diabetic patients with one or more risk factors 
for coronary artery disease revealed that 33% had an abnormal myocardial perfusion stress 
study. Smoking, duration of diabetes and cholesterol/HDL ratio were identified as 
independent predictors of an abnormal stress myocardial perfusion imaging (Scholte et al., 
2009). 
Some recent prospective studies in type 2 diabetes have been unable to link the number of 
risk factors to inducible ischemia on perfusion imaging (Wackers et al., 2004). That is 
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probably due to the fact that these studies did not account for the severity, duration, and 
effect of treatment of dyslipidemia and hypertension in patients with long-standing type 2 
diabetes. It is important to improve the ability to identify based on clinical data those 
patients at highest risk for cardiovascular events. While simple categorical risk factor 
burden has not proven to effectively discriminate which asymptomatic diabetic patients will 
or will not have ischemia on stress testing  it is possible that risk factor burden might predict 
risk of cardiovascular events in individual patients (Bax et al., 2007). Efforts have been made 
using data from Framingham, which included fewer than 400 diabetic subjects, the UKPDS 
(United Kingdom Prospective Diabetes Study) which included only newly diagnosed 
diabetic subjects and excluded patients with significant comorbidities and other populations 
(Guzder et al., 2005) to develop models that identify individuals at higher risk for 
cardiovascular events (Bax et al., 2007). It is necessary to define a subgroup of high risk 
asymptomatic patients that will benefit from silent ischemia screening.  
A substantial body of evidence has established that coronary artery calcium measurement 
provides potent risk stratification for asymptomatic diabetics. Diabetic patients with a low 
coronary artery calcium score have a very favourable prognosis. Among diabetics with a 
CAC score <10, the 5 year all cause mortality rate was extremely low and was similar to 
rates for those without diabetes and similar coronary artery calcium score. For any category 
of coronary artery calcium over zero, there a stepwise increased mortality risk in individual 
with diabetes compared to those without diabetes (Raggi et al., 2004). 
The study PREDICT (PRospective Evaluation of Diabetic Ischemic heart disease by 
Computed Tomography) a prospective cohort study on 589 asymptomatic type 2 diabetic 
patients showed that coronary artery calcium score was a highly significant independent 
predictor of cardiovascular events. A doubling in coronary artery calcium was associated 
with a 29% increase in risk of events (Elkeles et al., 2008). Coronary artery calcium provided 
greater predictive value for cardiac events than Framingham risk score and UKPDS risk 
scores, and than conventional and novel risk factors. In asymptomatic diabetic patients, the 
prevalence of stress induced ischemia increases the higher the coronary artery calcium score 
is on computed tomography scanning. From asymptomatic diabetic patients with coronary 
artery calcium score between 100 and 400, 23% had a positive stress SPECT scan, and 48% 
from those with coronary artery calcium score >400. This number increased to 71, 4% for 
asymptomatic diabetic patients with coronary artery calcium score >1000. The greater the 
extent of ischemia, the worse the clinical outcome and coronary artery calcium score was 
superior to established risk factors for predicting silent ischemia and cardiac events (Anand 
et al., 2006).  
It is now possible to test a new paradigm for screening asymptomatic diabetic patients 
(Berman et al., 2004). This consist of using coronary artery calcium scanning rather than 
cardiac stress testing as the first line screening test. Above coronary artery calcium threshold 
(400 or 100) SPECT-myocardial perfusion imaging could be selectively used for identifying 
high-risk silent ischemia. In the presence of high-risk ischemia coronary angiography 
should be performed, this being the group that could benefit from revascularization (He et 
al., 2000). It is expected that approximately one-third of such patients would have no 
detectable coronary artery calcium and many others would have coronary artery calcium 
scores at levels which obviate the need for SPECT-myocardial perfusion imaging. The 
inclusion of various clinical parameters as suggested by Bax et al. could alter the threshold 
criteria used to guide referral to stress testing respectively selective use of a lower coronary 
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artery calcium score threshold among those with high-risk clinical features. In patients with 
< 10% ischemia, repeat myocardial perfusion imaging might be appropriate in 3 years (Qu 
et al., 2003).  
There are continuing controversies regarding the screening for coronary artery disease in 
asymptomatic diabetic patients. Given the growing threat posed by increasing prevalence of 
diabetes, testing of algorithms which cost-effectively select for the identification of high-risk 
asymptomatic individuals with diabetes is urgently warranted.   
6. What are the implications of an early diagnosis of coronary 
atherosclerosis or ischemia? The detection of silent ischemia in diabetic 
patients impacts upon their treatment and outcome?  
Several recent prospective studies have addressed the value of screening for coronary artery 
disease in asymptomatic diabetic patients. The DIAD (Detection of Ischemia in 
Asymptomatic Diabetics) study is a randomized controlled trial in which 1123 patients with 
type 2 diabetes and no symptoms of coronary artery disease were randomly assigned to be 
screened with adenosine-stress radionuclide myocardial perfusion imaging  or not to be 
screened. The aim of the study was to test that systematic screening would identify higher-
risk individuals and beneficially affect their risk of myocardial infarction or cardiac death.  
In DIAD although type 2 diabetes is considered to be a coronary artery disease equivalent 
patients had a low cardiac event rate (0, 6%/year) and the identification of patients with 
abnormal screening did not serve to eliminate their risk over 5 years of follow-up. The 
cardiac event rate is 3-4 folds lower than that reported in previous retrospective studies on 
asymptomatic diabetic patients referred to nuclear cardiology laboratories. But these 
patients had a higher incidence of peripheral arterial disease, renal insufficiency and many 
were referred to preoperative evaluation (Rajagopalan et al., 2005; Zellweger et al., 2004). 
The favourable outcomes of patients in DIAD likely reflect in part the impact of aggressive, 
guideline-driven management of cardiac risk factors. One of the surprises of the DIAD was 
that there was no evidence for more inducible ischemia in screened patients when 
myocardial perfusion imaging was repeated after 3 years. Rather than greater prevalence of 
abnormal myocardial perfusion there was significantly less inducible ischemia at repeated 
imaging: 12% vs. 20%. A remarkable 79% of participants with initially abnormal stress 
myocardial perfusion at recruitment had resolution of ischemia. This improvement was not 
restricted to small perfusion defects but rather occurred regardless of the initial magnitude 
of perfusion defect. Only 10% of participants with initially normal screening myocardial 
perfusion imaging developed new inducible ischemia after 3 years. This resolution of 
ischemia was unanticipated but can be explained after the review of the medical regimens of 
participants. In the course of three years there was a significant increase in the treatment of 
patients with aspirin, statins and angiotensin converting enzyme inhibitors. The observed 
resolution of inducible ischemia was also a harbinger of the low cardiac events that 
subsequently emerged (Young et al., 2009). Routine screening for inducibile ischemia in 
asymptomatic patients with type 2 diabetes is not recommended because: the yield of 
detecting inducible ischemia is relatively low (Wackers et al., 2004); the overall cardiac event 
rate is low, even in patients with moderate or large defects and the highest event rate are 
conventionally assigned to an intermediate risk category; routine screening does not appear 
to affect overall outcome and routine screening of millions of asymptomatic diabetic 
patients is prohibitively expensive.  Although screening had no impact on outcomes in 
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DIAD it is noteworthy that stress myocardial perfusion imaging did effectively stratify 
patients into higher risk (moderate-large defects and ischemic ECG) and low-risk (small 
defects or normal myocardial perfusion imaging) subsets. On the other hand there were 
adverse cardiac events in both screened and unscreened patients. Thus DIAD results do not 
exclude the possibility that strategies to better identify patients at higher risk coupled with 
more effective treatment strategies might prove effective for screening in the future. A 
selective evaluation of asymptomatic diabetic patients will be a better approach for 
screening.  
The COURAGE (Clinical Outcomes Utlizing Revascularization and Aggresive Drug 
Evaluation) (Boden et al., 2006) reported among 2.287 patients with stable angina, overall 
event rates nearly 5%/year indicating a significant residual risk in intensively medically 
treated patients as well as those undergoing percutaneous interventions. These findings 
seem to highlight the need for improved methods to stratify residual risk within 
populations undergoing intensive medical management. Many of these patients had 
multivessel or proximal left anterior descending coronary artery disease and intensive 
medical treatment was as effective as percutaneous intervention combined with intensive 
medical treatment in preventing overall mortality or myocardial infarction. Results were 
similar in the approximate one-third of the subjects with diabetes. It may be not appropriate 
to extrapolate the results of this trial in symptomatic patients (in which the event rate for 
diabetic subjects approached 5% per year) to somewhat lower-risk asymptomatic patients. 
In the treatment arm of the CARDS (Collaborative Atorvastatin Diabetes Study) trial 
(Colhoun et al., 2004) which included individuals with type 2 diabetes and no history of 
cardiovascular disease even after risk factor modification in the active treatment group in 
whom LDL cholesterol was lowered, still the cardiovascular mortality of diabetic patients 
remains high; 1, 54/100 person-years. These findings suggest that type 2 diabetic patients 
being treated according to intensive treatment guidelines likely have a residual, 
intermediate risk (1-2% per year) for cardiac events. This high mortality will be due in part 
to silent, prognostically important coronary artery disease (left main, proximal left anterior 
descending, three vessel disease). Detection and revascularization of this disease will 
improve this poor prognosis (Sorajja et al., 2005, The BARI Investigators, 1997). This is an 
important argument for screening high risk diabetic patients for silent ischemia. In diabetic 
patients autopsy studies observed a greater prevalence of severe multivessel coronary artery 
disease among patients with diabetes compared with nondiabetic patients even in the 
absence of prior symptoms or clinical evidence of disease (Goraya et al., 2002). Thus the 
presumed benefit of evaluation of the presence and extent of myocardial ischemia is to 
identify those patients with left main or severe multivessel disease with a large area of 
myocardium at risk and who would have a benefit from coronary revascularization. 
Diabetic patients have a significant risk for atherosclerotic vascular disease and aggressive 
treatment of risk factors is recommended in the absence of symptomatic or known coronary 
artery disease. The role of coronary imaging is not to document the presence of 
atherosclerosis but to identify those with more extensive disease. Patients with myocardial 
ischemia involving a large segment of left ventricular myocardium are candidates for 
coronary angiography and subsequent revascularization. Available data (Hachamovitch et 
al., 2003, Sorajja et al., 2005) suggests that patients with ischemia involving 10% or more of 
the left ventricle have a better outcome after myocardial revascularization compared with 
the results of medical therapy alone.  
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The hypothesis that asymptomatic patients with severe ischemia benefit from 
revascularization above aggressive medical was subject of several prospective randomized 
trials some specifically targeted to the diabetic population. The BARI (Bypass Angioplasty 
Revascularization Investigation) trial evaluated the effectiveness of percutaneous coronary 
intervention versus coronary artery bypass grafting in over 1800 patients with symptomatic 
multivessel coronary artery disease (The BARI Investigators, 2007). The primary outcome of 
survival was similar in both groups. In a subgroup of patients with diabetes and multivessel 
disease coronary artery bypass grafting conferred higher survival rates (57,8%) versus 
percutaneous coronary intervention (45,5%) (p=0,025). The BARI 2D study Group (A 
Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease) ( The 
BARI 2D Study Group, 2009) randomly assigned 2368 patients with type 2 diabetes and 
stable ischemic heart disease to undergo either prompt revascularization with intensive 
medical therapy or intensive medical therapy alone. Overall there was no significant 
difference in rates of death and major cardiovascular events between patients undergoing 
prompt revascularization and those undergoing medical therapy. Prompt revascularization 
significantly reduced cardiovascular events as compared to medical therapy among patients 
who were selected to undergo coronary artery bypass grafting but not among those who 
were selected to undergo percutaneous coronary intervention. The study suggest that 
patients with diabetes, evidence of myocardial ischemia and extensive multivessel disease 
would benefit from prompt surgical revascularization mainly because of a lower rate of 
nonfatal myocardial infarction. Accurate and early diagnosis of coronary artery disease is 
likely of benefit in those patients with severe anatomic disease, where revascularization has 
particular benefits.  It is not recommended extensive and expensive diagnostic testing to 
define the presence of coronary artery disease before implementing medical therapy for 
established risk factors in diabetic patients. Negative screening tests in patients with 
diabetes do not uniformly confer a benign prognosis. Tests that detect inducible ischemia or 
assess atherosclerotic burden do not always identify patients at risk for plaque rupture and 
thrombosis which leads to acute coronary events. Further research focusing on the biological 
properties of the vessel wall and characterization of plaque structure and stability are 
warranted. Eventually, we will need better imaging techniques that can assess both plaque 
burden (soft and calcified) and the extent of vulnerable plaques. These techniques will 
require molecular imaging that permit delineation of plaque macrophage density and 
inflammatory markers, the thickness of the fibrous cap, the extent of the lipid-laden necrotic 
core, fibrin deposition, and the presence of neovessels (Davies et al., 2004; Jaffer et al., 2006; 
Waxman et al., 2006). If total plaque burden and some index of “vulnerability” could be 
detected noninvasively, at a reasonable cost, then this approach may be preferable to plaque 
coronary artery calcium imaging, which is merely reflective of the presence of 
atherosclerosis. Soft plaques, as previously mentioned, are missed, and no information on 
vulnerability to rupture is obtained (Beller, 2007).  
7. Conclusion  
Although the coronary artery disease asymptomatic patient with diabetes is by definition at 
least at intermediate risk for cardiovascular events it is difficult to support routine screening 
for these patients. As previous recommendations for stratifying diabetic patients based upon 
the number of risk factors have not proven effective the question remains whether there are 
individuals with diabetes in whom coronary artery imaging would seem particularly 
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appropriate. The motivation of such testing would be the clinical suspicion that the 
individual is at high risk for having a coronary artery disease event in the short term. What 
would be the best strategy for identifying at-risk individuals is still under debate. In patients 
evaluated clinically to be at high risk coronary artery calcium scoring may be reasonable 
first test with subsequent functional imaging performed if the calcium scoring indicates a 
substantial atherosclerotic burden. The concept of screening asymptomatic subjects is 
heavily debated and the controversy can only be resolved by gathering evidence for or 
against screening, which requires data from a randomized clinical trial.  
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